CY1115770T1 - PHARMACEUTICAL SPHEREOID - Google Patents

PHARMACEUTICAL SPHEREOID

Info

Publication number
CY1115770T1
CY1115770T1 CY20141100847T CY141100847T CY1115770T1 CY 1115770 T1 CY1115770 T1 CY 1115770T1 CY 20141100847 T CY20141100847 T CY 20141100847T CY 141100847 T CY141100847 T CY 141100847T CY 1115770 T1 CY1115770 T1 CY 1115770T1
Authority
CY
Cyprus
Prior art keywords
spheroids
contain
pharmaceutical
coating
degradable
Prior art date
Application number
CY20141100847T
Other languages
Greek (el)
Inventor
Helen Kathleen Danagher
Geoffrey Gerard Hayes
Hassan Mohammad
Malcolm Walden
Jonathon Oliver Whitehouse
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0605271A external-priority patent/GB0605271D0/en
Priority claimed from GB0605542A external-priority patent/GB0605542D0/en
Priority claimed from GB0617272A external-priority patent/GB0617272D0/en
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of CY1115770T1 publication Critical patent/CY1115770T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Σύμφωνα προς την εφεύρεση χρησιμοποιούνται μονοστεατικός γλυκερυλεστέρας και πολυμερικό συνδετικό ως βοηθητικά σφαιροποίησης στην βιομηχανική κατασκευή φαρμακευτικών σφαιροειδών που δεν περιέχουν ή ουσιαστικώς δεν περιέχουν μικροκρυσταλλική κυτταρίνη. Τα σφαιροειδή μπορεί να περιέχουν έναν ή περισσότερους θεραπευτικώς δραστικούς παράγοντες που δεν υφίστανται αποικοδόμηση ή ουσιαστικώς δεν υφίστανται αποικοδόμηση όταν αποθηκεύονται υπό συνθήκες επιταχυνόμενης θερμοκρασίας και υγρασίας. Στα σφαιροειδή μπορεί να εφαρμόζεται μια επικάλυψη· όταν υπάρχει, η επικάλυψη κατά προτίμηση είναι επικάλυψη ελεγχόμενης απελευθέρωσης.According to the invention glyceryl monostearate and polymeric binder are used as pelletizing aids in the manufacture of pharmaceutical spheroids that do not contain or substantially do not contain microcrystalline cellulose. Spheroids may contain one or more therapeutically active agents that are non-degradable or substantially non-degradable when stored under accelerated temperature and humidity conditions. A coating may be applied to the spheroids; when present, the coating is preferably a controlled release coating.

CY20141100847T 2006-03-16 2014-10-15 PHARMACEUTICAL SPHEREOID CY1115770T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0605271A GB0605271D0 (en) 2006-03-16 2006-03-16 Pharmaceutical spheroids
GB0605542A GB0605542D0 (en) 2006-03-20 2006-03-20 Pharmaceutical Spheroids
GB0617272A GB0617272D0 (en) 2006-09-04 2006-09-04 Pharmaceutical spheroids
EP07733554.5A EP2001445B1 (en) 2006-03-16 2007-03-16 Pharmaceutical spheroids

Publications (1)

Publication Number Publication Date
CY1115770T1 true CY1115770T1 (en) 2017-01-25

Family

ID=38191129

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100847T CY1115770T1 (en) 2006-03-16 2014-10-15 PHARMACEUTICAL SPHEREOID

Country Status (13)

Country Link
US (1) US9034373B2 (en)
EP (1) EP2001445B1 (en)
JP (2) JP5443768B2 (en)
CY (1) CY1115770T1 (en)
DK (1) DK2001445T3 (en)
ES (1) ES2516693T3 (en)
HR (1) HRP20141001T1 (en)
ME (1) ME02135B (en)
PL (1) PL2001445T3 (en)
PT (1) PT2001445E (en)
RS (1) RS53624B1 (en)
SI (1) SI2001445T1 (en)
WO (1) WO2007105016A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2001445E (en) * 2006-03-16 2014-10-24 Euro Celtique Sa Pharmaceutical spheroids
AT511581A1 (en) 2011-05-26 2012-12-15 G L Pharma Gmbh ORAL RETARDANT FORMULATION
FR3080278B1 (en) * 2018-04-11 2021-04-30 Ghs Patents Ltd PROCESS FOR MANUFACTURING A CANNABIDIOL SPHEROIDE

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2471784A1 (en) * 1979-12-21 1981-06-26 Roussel Uclaf EXTENDED ACTION ANTIARRHYTHMIC DRUGS WITH THE ACTIVE INGREDIENT AS A / 2- / BIS (1-METHYLETHYL) AMINO / ETHYL / -A-PHENYL-2-PYRIDINE ACETAMIDE OR SALTS THEREOF, AND THE PROCESS FOR THE PREPARATION OF THESE MEDICAMENTS AND COMPOSITIONS INCLUDING THEM
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
SE9200858L (en) * 1992-03-20 1993-09-21 Kabi Pharmacia Ab Method for producing delayed release pellets
EP0654263B1 (en) * 1993-11-23 2002-01-23 Euro-Celtique S.A. Method for preparing a sustained release composition
DE4415921A1 (en) 1994-05-05 1995-11-09 Bayerische Motoren Werke Ag Device for damping vibrations in a gear shift device for vehicles
JPH10501235A (en) * 1994-06-03 1998-02-03 ザ、プロクター、エンド、ギャンブル、カンパニー Fast dissolving dosage form
US5458823A (en) 1994-10-28 1995-10-17 Fuisz Technologies Ltd. Method and apparatus for spinning feedstock material
CN1093758C (en) * 1994-12-19 2002-11-06 第一制药株式会社 Sustained-released granular preparation and process for producing the same
KR100404293B1 (en) 1995-05-02 2004-02-18 다이쇼 세이야꾸 가부시끼가이샤 Composition for Oral Administration
JP5042447B2 (en) * 1995-07-21 2012-10-03 第一三共株式会社 Mixed preparation
AU700961B2 (en) 1995-07-21 1999-01-14 Daiichi Pharmaceutical Co., Ltd. Granular preparation and producing process thereof
US5851454A (en) 1997-06-13 1998-12-22 Fuisz Technologies, Ltd. Spinner head having flow restricting inserts
RS49982B (en) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
US6117452A (en) 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
CN1343128B (en) 1999-03-17 2010-04-21 第一制药株式会社 Medicinal compositions
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
DE60211130T2 (en) * 2001-02-13 2006-11-30 Astrazeneca Ab NEW FORMULATION WITH MODIFIED RELEASE
KR100712356B1 (en) 2003-01-23 2007-05-02 (주)아모레퍼시픽 Sustained-release preparations and method for producing the same
JP2007516220A (en) 2003-05-06 2007-06-21 ビーピーエスアイ ホールディングス，インコーポレーテッド Method for producing thermoforming composition containing acrylic polymer adhesive, pharmaceutical preparation and method for producing the preparation
PT2001445E (en) * 2006-03-16 2014-10-24 Euro Celtique Sa Pharmaceutical spheroids

Also Published As

Publication number Publication date
JP2014088363A (en) 2014-05-15
PL2001445T3 (en) 2015-06-30
DK2001445T3 (en) 2014-10-27
US20100047337A1 (en) 2010-02-25
PT2001445E (en) 2014-10-24
JP5443768B2 (en) 2014-03-19
HRP20141001T1 (en) 2014-12-05
EP2001445A1 (en) 2008-12-17
JP2009530258A (en) 2009-08-27
ME02135B (en) 2015-04-30
WO2007105016A1 (en) 2007-09-20
US9034373B2 (en) 2015-05-19
RS53624B1 (en) 2015-04-30
EP2001445B1 (en) 2014-07-23
ES2516693T3 (en) 2014-10-31
SI2001445T1 (en) 2015-02-27

Similar Documents

Publication Publication Date Title
CY1126116T1 (en) PHARMACEUTICAL COMPOSITIONS CONSISTING OF NILOTINIB
EP4218735A3 (en) Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
JP2012500203A5 (en)
DK2148670T3 (en) Titration of tapentadol
CY1117287T1 (en) PYRROLIDINONE AS METAP-2 Suspensions
EA201291028A1 (en) POLYPROPYLENE COMPOSITION, SUITABLE FOR COATING EXTRUSION
HRP20110861T1 (en) Drug for treatment of influenza
BR112012010270A2 (en) mentisulfonylmethane (msm) for treatment of drug resistant microorganisms
MX342643B (en) Pharmaceutical dosage forms comprising poly(e-caprolactone).
CL2012002771A1 (en) Compounds of substituted aryletinyl, modulators of mglur5 receptors; obtaining process; pharmaceutical composition; and its use in the treatment or prevention of schizophrenia, cognitive diseases, x fragile syndrome or autism.
CL2008002243A1 (en) Compounds derived from 2-pyrazolamino-1,3,5-triazine, jak kinase inhibitors; preparation procedure; pharmaceutical composition; and use for the treatment of cancer.
CY1116056T1 (en) Antibacterial Combination Therapy For The Treatment Of Gram Positive Bacterial Infections
WO2009061221A3 (en) Agent stabilisation process and product
WO2007084728A3 (en) 2-imino-benzimidazoles
EA200802111A1 (en) IMPLANTS FOR THE TREATMENT OF THE STATES ASSOCIATED WITH DOPAMIN
TW200628534A (en) Retention and drainage aids
CY1115770T1 (en) PHARMACEUTICAL SPHEREOID
BRPI0914305B8 (en) substituted carboxamide pyridazine compounds as kinase inhibitor compounds, use of the compounds and use of a composition comprising the compounds
CY1119493T1 (en) METHODS AND COMPOSITIONS FOR THE APPLICATION OF MOXIFLOXACINE TO IT
TR200904159A1 (en) Modified release emoxipine formulations.
CY1116831T1 (en) USE 24-norUDCA
MX2012007365A (en) Slow release pharmaceutical compositions of iloperidone.
CY1108231T1 (en) STABLE SOLID DOSOLOGICAL FORM INCLUDING DESMOPRESIN
MX2009009490A (en) Novel prodrugs.
ATE497991T1 (en) STABILIZER COMPOSITION CONTAINING PHOSPHITESTERS